StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $31.17 | $31.16 | -0.03% | 4.1M |
| 05-15 | $31.17 | $31.18 | +0.03% | 2.3M |
| 05-18 | $31.16 | $31.23 | +0.24% | 4.2M |
| 05-19 | $31.20 | $31.21 | +0.03% | 3.0M |
| 05-20 | $31.21 | $31.25 | +0.13% | 2.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for CPRX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $149.39M | $588.99M | $436.38M | $287.98M |
Operating Income | $73.23M | $257.78M | $195.93M | $129.66M |
Net Income | $63.73M | $214.33M | $161.63M | $52.11M |
EPS (Diluted) | $0.50 | $1.68 | $1.27 | $0.86 |
Total Assets | $1.15B | $1.10B | $1.05B | $971.91M |
Total Liabilities | $134.91M | $149.71M | $131.36M | $115.89M |
Cash & Equivalents | $755.86M | $709.17M | $689.89M | $652.80M |
Free Cash Flow OCF − CapEx | $59.56M | $208.61M | $163.75M | $131.31M |
Shares Outstanding | 122.18M | 122.51M | 123.26M | 122.39M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.